Tenet Healthcare THC shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $27 to $60.
Tenet is a Dallas-based healthcare provider organization operating a collection of hospitals (65) and many outpatient facilities, including ambulatory surgery centers, urgent care centers, freestanding imaging centers, freestanding emergency rooms/micro-hospitals, and physician practices across the United States.
Tenet Healthcare shares were trading up 2.82% at $46. The stock has a 52-week high of $48.11 and a 52-week low of $10.
CVS Health CVS shares are trading higher after Jefferies upgraded the stock from Hold to Buy and announced a $90 price target.
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing about 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S.
CVS Health shares were trading up 1.91% at $75.40. The stock has a 52-week high of $76.44 and a 52-week low of $52.04.
Thermo Fisher Scientific TMO shares are trading higher after Credit Suisse upgraded the stock from Neutral to Outperform and raised its price target from $490 to $556 per share.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents.
Thermo Fisher Scientific shares were trading up 1.86% at $509.76. The stock has a 52-week high of $532.57 and a 52-week low of $250.21.
Sarepta Therapeutics SRPT shares are trading lower after the company reported its 102 Study Evaluating its SRP-9001 did not achieve statistical significance on the primary functional endpoint of improvement in NSAA total score compared to Placebo at 48 weeks.
Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates.
Sarepta Therapeutics shares were trading down 50.58% at $83.49. The stock has a 52-week high of $181.83 and a 52-week low of $78.06.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.